The breakthrough designation cohort shows no signs of slowed growth, as the FDA grants 'all-hands-on-deck' attention to a total of 68 therapeutics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Breakthrough programme turns two. Nat Rev Drug Discov 13, 873–875 (2014). https://doi.org/10.1038/nrd4487
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4487
This article is cited by
-
2014 FDA drug approvals
Nature Reviews Drug Discovery (2015)